ClinicalTrials.gg
CompletedNCT00532155VITALUpdated Sep 10, 2025Results posted

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

A Phase 3 interventional study of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) and Placebo in Carcinoma and Non Small Cell Lung, sponsored by Sanofi. Completed at 32 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
913
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 402 studies in Carcinoma with a site in United States — 70 open to participants now, 112 under way, 19 of them phase 3. Carcinoma · United States.

Enrollment
9th of 358
913 · median 48
Started
2007
with 9 others
Phase 3
49 of 402
6 open now
Registered
67th of 402
by date

Among the 402 studies in Carcinoma with a site in United States, this one is the 9th largest by enrollment of the 358 interventional ones that give a count, is one of 10 that started in 2007, is one of 49 in phase 3, and was the 67th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

70 of the 402 studies in Carcinoma with a site in United States are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 402 studies in Carcinoma with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC).

The secondary objectives were to compare other efficacy parameters, to assess the overall safety of the two treatment arms, to assess the pharmacokinetics of intravenous (IV) aflibercept in this participant population and to determine immunogenicity of IV aflibercept in all participants.

Read the detailed description

The study included:

  • A screening visit of up to 21 days prior to randomization
  • Randomization at baseline (Treatment was initiated with 3 days of randomization)
  • A treatment period with 3-week treatment cycles until the participant met the following discontinuation criteria: had progressive disease, had unacceptable toxicity, or refused further study treatment
  • A post study treatment follow-up period (a visit was scheduled every 8 weeks until death or end of study)
03

Conditions studied

  • Carcinoma
  • Non Small Cell Lung

Keywords

  • lung cancer
  • angiogenesis inhibitor
  • chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological/cytological proven locally advanced or non-small cell lung cancer
  • Disease progression during or after one, and only one, prior anticancer therapy which is platinum-based for advanced or metastatic disease
  • (ECOG) performance status 0, 1 or 2
  • Adequate renal, liver and bone marrow functions

Exclusion criteria

Exclusion Criteria:

  • Squamous histology/cytology
  • Less than 28 days elapsed from prior treatment with radiotherapy, surgery, or chemotherapy to the time of randomization
  • Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to > 25% of bone marrow
  • Prior docetaxel treatment
  • Uncontrolled hypertension

The above information was not intended to contain all considerations relevant to participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
913 participants (actual)

Study arms

  • Experimental
    Aflibercept/Docetaxel

    Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Aflibercept immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.

    Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) · Drug: Docetaxel (Taxotere®) · Drug: Dexamethasone (pre- and post-medication for docetaxel)

  • Placebo comparator
    Placebo/Docetaxel

    Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Placebo immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.

    Drug: Placebo · Drug: Docetaxel (Taxotere®) · Drug: Dexamethasone (pre- and post-medication for docetaxel)

Interventions

  • 6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.

  • DrugPlacebo

    Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.

  • 75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.

  • DrugDexamethasone (pre- and post-medication for docetaxel)

    Drug page: Dexamethasone

    As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was time interval from the date of randomization to the date of death due to any cause. If death was not observed during the study, overall survival time was censored at the last date the participant was known to be alive, or the study cutoff date, whichever was earlier. The cut-off date for the OS was date when 687 deaths were observed. OS was estimated from Kaplan-Meier Curves.

    Time frame: Baseline to the date when 687 deaths occurred (26 January 2011)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time interval between the date of randomization and the time of occurrence of the first radiological tumor progression detected by a computer tomography (CT) scan and /or by Magnetic Resonance Imaging (MRI); or death due to any cause; whichever was earlier. Participants without disease progression were censored at the earliest date between their last valid tumour assessment and the data cutoff date. PFS was estimated from Kaplan-Meier Curves.

    Time frame: Baseline to data cut-off (26 January 2011)

  2. Overall Response (OR) Rate as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria

    Participants with OR were those who had a confirmed complete response \[CR\] or a confirmed partial response \[PR\], based on RECIST criteria, in which * CR refected the disappearance of all tumor lesions (with no new tumors) * PR reflected a pre-defined decrease in tumor burden - a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD * OR was CR + PR The response rate was the percent of participants with a response. To determine a response, tumors were assessed by the investigators using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks.

    Time frame: Baseline to data cut-off (26 January 2011)

  3. Health Related Quality of Life (HRQL) Assessed by the Lung Cancer Symptom Scale (LCSS)

    HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies (appetite, fatigue, cough, dyspnea, hemoptysis and pain), and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. The LCSS total score was defined as the mean of the 9 items of the scale, each scored between 0 (for best outcome) to 100 (for worst outcome).

    Time frame: Baseline (prior to first dose), at cycles 2 and 4 and at the end of study therapy.

  4. Health Related Quality of Life (HRQL) Assessed by the Average Symptom Burden Index (ASBI)

    HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies, and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. ABSI was the mean score for the six major lung cancer symptoms (appetite, fatigue, cough, dyspnea, hemoptysis and pain), each scored between 0 (for best outcome) to 100 (for worst outcome).

    Time frame: Baseline (prior to first dose), at cycles 2 and 4 and at the end of study therapy.

07

Results

Posted Jan 1, 2013

Participant flow

Participant flow — Overall Study
MilestonePlacebo/DocetaxelAflibercept/Docetaxel
Started457456
Safety population455450
Completed00
Not completed457456
Withdrew: Adverse event66123
Withdrew: Lack of efficacy332255
Withdrew: Protocol violation13
Withdrew: Lost to follow-up20
Withdrew: Physician decision1615
Withdrew: Withdrawal by subject2344
Withdrew: Consent withdrawn57
Withdrew: Moved10
Withdrew: Pre-existing brain metastasis (by mri)10
Withdrew: Occurence of a second cancer01
Withdrew: Occurence of a secondary cancer01
Withdrew: Promotor ended study10
Withdrew: Progressive disease (by incorrect scan)01
Withdrew: Had brain metastasis, was mis-randomized10
Withdrew: Study stopped10
Withdrew: Study terminated by sponsor10
Withdrew: Study termination stop further treatment40
Withdrew: Did not receive study medication26

Outcome measures

PrimaryOverall Survival (OS)

OS was time interval from the date of randomization to the date of death due to any cause. If death was not observed during the study, overall survival time was censored at the last date the participant was known to be alive, or the study cutoff date, whichever was earlier. The cut-off date for the OS was date when 687 deaths were observed. OS was estimated from Kaplan-Meier Curves.

Time frame:
Baseline to the date when 687 deaths occurred (26 January 2011)
Reported as:
Median · months
Overall Survival (OS)
monthsPlacebo/DocetaxelAflibercept/Docetaxel
Overall Survival (OS)10.41 (9.199 to 11.860)10.05 (9.166 to 11.598)
Statistical analysis
  • Placebo/Docetaxel vs Aflibercept/Docetaxel · Stratified log-rank test · p = 0.8985 · Hazard ratio (hr): 1.01 · 95% CI 0.868 to 1.174Stratified on ECOG Performance Status (0 vs 1 vs 2) and Prior Bevacizumab (yes vs no) according to IVRS.
SecondaryProgression Free Survival (PFS)

PFS was defined as the time interval between the date of randomization and the time of occurrence of the first radiological tumor progression detected by a computer tomography (CT) scan and /or by Magnetic Resonance Imaging (MRI); or death due to any cause; whichever was earlier. Participants without disease progression were censored at the earliest date between their last valid tumour assessment and the data cutoff date. PFS was estimated from Kaplan-Meier Curves.

Time frame:
Baseline to data cut-off (26 January 2011)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPlacebo/DocetaxelAflibercept/Docetaxel
Progression Free Survival (PFS)4.11 (3.515 to 4.337)5.19 (4.370 to 5.552)
Statistical analysis
  • Placebo/Docetaxel vs Aflibercept/Docetaxel · Stratified Log-Rank test · p = 0.0035 · Stratified hazard ratio: 0.819 · 95% CI 0.716 to 0.937Stratified on ECOG Performance Status (0 vs 1 vs 2) and Prior Bevacizumab (yes vs no) according to IVRS.
SecondaryOverall Response (OR) Rate as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria

Participants with OR were those who had a confirmed complete response \[CR\] or a confirmed partial response \[PR\], based on RECIST criteria, in which * CR refected the disappearance of all tumor lesions (with no new tumors) * PR reflected a pre-defined decrease in tumor burden - a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD * OR was CR + PR The response rate was the percent of participants with a response. To determine a response, tumors were assessed by the investigators using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks.

Time frame:
Baseline to data cut-off (26 January 2011)
Reported as:
Number · percentage of participants
Overall Response (OR) Rate as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria
percentage of participantsPlacebo/DocetaxelAflibercept/Docetaxel
Complete Response (CR) rate0.20.2
Partial Response (PR) rate8.623.0
Overall Response (OR) rate8.938.6
SecondaryHealth Related Quality of Life (HRQL) Assessed by the Lung Cancer Symptom Scale (LCSS)

HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies (appetite, fatigue, cough, dyspnea, hemoptysis and pain), and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. The LCSS total score was defined as the mean of the 9 items of the scale, each scored between 0 (for best outcome) to 100 (for worst outcome).

Time frame:
Baseline (prior to first dose), at cycles 2 and 4 and at the end of study therapy.
Reported as:
Mean · units on a scale
Health Related Quality of Life (HRQL) Assessed by the Lung Cancer Symptom Scale (LCSS)
units on a scalePlacebo/DocetaxelAflibercept/Docetaxel
Baseline (N=431, N=428)29.52 ± 17.0331.54 ± 18.03
Cycle 2 (N=329, N=315)29.50 ± 16.7230.54 ± 16.78
Cycle 4 (N=211, N=240)27.67 ± 16.2429.61 ± 16.92
End of treatment (N=254, N=240)34.82 ± 18.3436.07 ± 18.81
SecondaryHealth Related Quality of Life (HRQL) Assessed by the Average Symptom Burden Index (ASBI)

HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies, and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. ABSI was the mean score for the six major lung cancer symptoms (appetite, fatigue, cough, dyspnea, hemoptysis and pain), each scored between 0 (for best outcome) to 100 (for worst outcome).

Time frame:
Baseline (prior to first dose), at cycles 2 and 4 and at the end of study therapy.
Reported as:
Mean · units on a scale
Health Related Quality of Life (HRQL) Assessed by the Average Symptom Burden Index (ASBI)
units on a scalePlacebo/DocetaxelAflibercept/Docetaxel
Baseline (N=429, N=429)26.17 ± 16.3028.24 ± 16.91
Cycle 2 (N=327, N=316)26.23 ± 15.9327.05 ± 15.92
Cycle 4 (N=211, N=241)24.52 ± 15.2226.19 ± 16.38
End of treatment (N=253, N=239)30.73 ± 17.2631.19 ± 18.12

Adverse events

Collected over From treatment initiation to October 21, 2011. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/Docetaxel—159/453 (35.1%)388/453 (85.7%)
Aflibercept/Docetaxel—218/452 (48.2%)402/452 (88.9%)
Most frequent serious events
Showing 10 of 192
Most frequent serious events
EventPlacebo/DocetaxelAflibercept/Docetaxel
Disease progressionGeneral disorders12/45333/452
Febrile neutropeniaBlood and lymphatic system disorders17/45321/452
PneumoniaInfections and infestations20/45315/452
NeutropeniaBlood and lymphatic system disorders7/45316/452
DyspnoeaRespiratory, thoracic and mediastinal disorders14/45313/452
StomatitisGastrointestinal disorders0/45313/452
Neutropenic infectionInfections and infestations11/45311/452
Neutropenic sepsisInfections and infestations3/45310/452
Pulmonary embolismRespiratory, thoracic and mediastinal disorders8/4538/452
DiarrhoeaGastrointestinal disorders3/4538/452
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlacebo/DocetaxelAflibercept/Docetaxel
StomatitisGastrointestinal disorders69/453180/452
AlopeciaSkin and subcutaneous tissue disorders148/453133/452
FatigueGeneral disorders130/453142/452
DiarrhoeaGastrointestinal disorders106/453124/452
Decreased appetiteMetabolism and nutrition disorders93/453122/452
Weight decreasedInvestigations35/453110/452
CoughRespiratory, thoracic and mediastinal disorders94/453108/452
HypertensionVascular disorders23/45395/452
NauseaGastrointestinal disorders92/45379/452
EpistaxisRespiratory, thoracic and mediastinal disorders28/45390/452

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo/DocetaxelAflibercept/DocetaxelTotal
Mean59.6 ± 9.459.6 ± 9.559.6 ± 9.4
Age, Customized
Age, Customized(participants)Placebo/DocetaxelAflibercept/DocetaxelTotal
<65 years316315631
>= and <75 years122121243
>=75 years192039
Sex/Gender, Customized
Sex/Gender, Customized(participants)Placebo/DocetaxelAflibercept/DocetaxelTotal
Male300305605
Female157151308
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo/DocetaxelAflibercept/DocetaxelTotal
Caucasian/White405411816
Black10717
Asian/Oriental403474
Other246
Body Surface Area (BSA)
Body Surface Area (BSA)(m²)Placebo/DocetaxelAflibercept/DocetaxelTotal
Mean1.8 ± 0.21.8 ± 0.21.8 ± 0.2
Prior Bevacizumab (as per IVRS)
Prior Bevacizumab (as per IVRS)(participants)Placebo/DocetaxelAflibercept/DocetaxelTotal
Yes5351104
No404405809
Eastern Cooperative Oncology Group (ECOG) performance status score (as per IVRS)
Eastern Cooperative Oncology Group (ECOG) performance status score (as per IVRS)(participants)Placebo/DocetaxelAflibercept/DocetaxelTotal
Participants with ECOG Score = 0151149300
Participants with ECOG Score = 1283286569
Participants with ECOG Score = 2232144
08

Study locations

32 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Buenos Aires, Argentina
  • sanofi-aventis Australia & New Zealand administrative office
    Macquarie Park, New South Wales, Australia
  • Sanofi-Aventis Administrative Office
    Vienna, Austria
  • Sanofi-Aventis Administrative Office
    São Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Sofia, Bulgaria
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Santiago, Chile
  • Sanofi-Aventis Administrative Office
    Shanghai, China
  • Sanofi-Aventis Administrative Office
    Prague, Czechia
  • Sanofi-Aventis Administrative Office
    Tallinn, Estonia
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
  • Sanofi-Aventis Administrative Office
    Athens, Greece
  • Sanofi-Aventis Administrative Office
    Causeway Bay, Hong Kong
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Mumbai, India
  • Sanofi-Aventis Administrative Office
    Milan, Italy
  • Sanofi-Aventis Administrative Office
    Kuala Lumpur, Malaysia
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Warsaw, Poland
  • Sanofi-Aventis Administrative Office
    Porto Salvo, Portugal
  • Sanofi-Aventis Administrative Office
    Bucharest, Romania
  • Sanofi-Aventis Administrative Office
    Moscow, Russia
  • Sanofi-Aventis Administrative Office
    Singapore, Singapore
  • Sanofi-Aventis Administrative Office
    Seoul, South Korea
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
  • Sanofi-Aventis Administrative Office
    Taipei, Taiwan
  • Sanofi-Aventis Administraive Office
    Istanbul, Turkey (Türkiye)
  • Sanofi-Aventis Admnistrative Office
    Guildford Surrey, United Kingdom
09

References and documents

Publications

  • Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, Baldotto C, Bennouna J, Shepherd FA, Le-Guennec S, Rey A, Miller V, Thatcher N, Scagliotti G. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol. 2012 Oct 10;30(29):3640-7. doi: 10.1200/JCO.2012.42.6932. Epub 2012 Sep 10. PubMed 22965962 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Jan 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 2 years after primary completion. A results delay was requested in Feb 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2007
First posted
Sep 20, 2007
Start
Sep 2007
Primary completionActual
Jan 2011
CompletionActual
Oct 2011
Results delay requested
Feb 17, 2012
Results first posted
Jan 1, 2013
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00532155
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 20, 2007
Start date
Sep 2007
Primary completion
Jan 2011
Completion
Oct 2011
Results posted
Jan 1, 2013
Last update
Sep 10, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion